Head to Head Review: Sanofi (NASDAQ:SNY) vs. Scilex (NASDAQ:SCLX)Defense World · Oct 11, 2026
Iterum Therapeutics (NASDAQ:ITRM) vs. Scilex (NASDAQ:SCLX) Critical ReviewDefense World · Sep 28, 2026
Head to Head Survey: Scilex (NASDAQ:SCLX) versus Incannex Healthcare (NASDAQ:IXHL)Defense World · Sep 26, 2026Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.18 | -$16.65 | Miss |
| May 20, 2026 | -$0.21 | -$4.76 | Miss |
| Apr 10, 2026 | -$0.29 | -$4.60 | Miss |
| Nov 14, 2025 | -$13.80 | -$13.80 | Beat |
| Aug 12, 2025 | -$0.57 | -$4.62 | Miss |
| May 14, 2025 | -$4.20 | -$2.26 | Beat |